SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-244711
Filing Date
2022-09-14
Accepted
2022-09-14 16:01:04
Documents
14
Period of Report
2022-09-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d408311d8k.htm   iXBRL 8-K 30200
2 EX-99.1 d408311dex991.htm EX-99.1 9688
6 GRAPHIC g408311g0914011904016.jpg GRAPHIC 2907
  Complete submission text file 0001193125-22-244711.txt   170956

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrix-20220912.xsd EX-101.SCH 2858
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20220912_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20220912_pre.xml EX-101.PRE 11263
8 EXTRACTED XBRL INSTANCE DOCUMENT d408311d8k_htm.xml XML 3356
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 221243008
SIC: 2834 Pharmaceutical Preparations